Connection

John Wrangle to Treatment Outcome

Back to Details
This is a "connection" page, showing publications John Wrangle has written about Treatment Outcome.
John Wrangle
Connection Strength
0.121
Treatment Outcome
  1. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2018 05; 19(5):694-704.
    View in: PubMed
    Score: 0.066
  2. Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma. Cell Rep Med. 2021 10 19; 2(10):100426.
    View in: PubMed
    Score: 0.021
  3. Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma. Clin Cancer Res. 2018 11 01; 24(21):5250-5260.
    View in: PubMed
    Score: 0.017
  4. The clinical implications of immunogenomics in colorectal cancer: A path for precision medicine. Cancer. 2018 04 15; 124(8):1650-1659.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.